I don't think this really fixes anything. Having a non automatic closer maybe reverses 2 or 3 games but like I've stated constantly there are multiple games where it is NOT on the closing performance where we can point at.
And at best, you have to drop 15 million on him. The Braves are going to probably have to spend on outfield, so how much money does that leave left? Even Markakis costs 10 most likely and then that might very well be it.
So where do you propose AA spends the windfall that's coming?
They're not likely to spend a dime on the rotation, CF, LF (or RF if Acuna shifts over), 1B, 2B, or SS.
Unless they drop a lot of money on extensions, you're still going to have a huge chunk of change to spend, more than enough to give $15 million per to Kimbrel, Moustakas, and Markakis or his replacement if they decide to go that way. I think most people understand you guys when you point out that a Closer isn't the most optimal place to spend your money, but the only other "needs" will be Markakis' spot, someone to share time with Camargo at 3B (if they don't give Riley the job), and the pen.
There's really no need to spend big to get someone to split time with Flowers - although trading for Realmuto remains a strong possibility, he's not due to make big money. While the money's there, I don't think anyone realistically sees AA as getting into the Harper bidding war. Maybe Brantley's healthy season pushes AA towards him rather than bringing back Markakis or he chooses to bring in Moustakas to pair with Camargo, but you're still likely looking at ~ $15 million AAV players there.
The 2019 payroll currently sits in the $50,350,000 range before extensions and arbitration raises. From the current 40-Man Roster, we can probably expect Lindgren, Whitley, Jose Ramirez, Lane Adams, Flaherty, and possibly Reed to be non-tendered this winter while Anibal likely is allowed to walk. There's not going to be a need to pinch pennies for the first time in forever, and adding a lockdown Closer makes some sense - even if that guy's not Kimbrel.